Timothy Colin Hardman (Timothy C Hardman, Tim Hardman)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Nitric Oxide Synthase

Community Dwelling

Coronavirus Disease

Top Venues

Drugs in context

This page only lists publications with an associated author ORCID identifier.

Publications

Timothy Colin Hardman, Rob Aitchison, Richard Scaife, Jean Edwards, Gill Slater
The future of clinical trials and drug development: 2050. Drugs in context 12 (2023)
Liam G Heaney, John Busby, Catherine E Hanratty, Ratko Djukanović, Ashley Woodcock, Samantha Walker, Timothy Colin Hardman, Joseph R Arron, David F Choy, Peter Bradding, Christopher E Brightling, Rekha Chaudhuri, Douglas Cowan, Adel Hasan Mansur, Stephen J Fowler, Christopher E Brightling, Peter Howarth, James Lordan, Andrew N Menzies-Gow, Timothy Harrison, Douglas S Robinson, Cecile T J Holweg, John G Matthews, Ian Douglas Pavord, Liam G Heaney
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. American journal of respiratory and critical care medicine 206 (5) (2022)
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Luydmila Yu Akhieva, Elena V Kuntsevich, Anastasia A Troshina, Elena I Kvasova, Anton A Tikhonov, Nadezhda F Khomyakova, Francisco Harrison, Jean-François Rossi, Timothy Colin Hardman
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. Drugs in context 11 (2022)
Ronald Kompier, Pieter Neels, Walter Beyer, Timothy Colin Hardman, Dmitry Lioznov, Susanna Kharit, Mikhail Petrovich Kostinov
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. F1000Research 11 (2022)
Ronald Kompier, Pieter Neels, Walter Beyer, Timothy Colin Hardman, Dmitry Lioznov, Susanna Kharit, Mikhail Petrovich Kostinov
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. F1000Research 11 (2022)
Herbert Nar, Gisela Schnapp, Oliver T Hucke, Timothy Colin Hardman, Thomas Klein
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. ChemMedChem 16 (9) (2021)
David-Gómez Cabrero, Stefan Walter, Imad Abugessaisa, Rebeca Miñambres-Herraiz, Lucia Bernad Palomares, Lee Butcher, Jorge D Erusalimsky, Francisco José García-García, José Carnicero, Timothy Colin Hardman, Harald Mischak, Petra Zürbig, Matthias Hackl, Johannes Grillari, Edoardo Fiorillo, Francesco Cucca, Beatrice Arosio, Isabelle Carrie, Marco Colpo, Stefania Bandinelli, Catherine Feart, Karine Peres, Jean-François Dartigues, Catherine Helmer, José Viña, Gloria Olaso, Irene García-Palmero, Jorge García Martínez, Pidder Jansen-Dürr, Tilman Grune, Daniela Weber, Gian Luca Salvagno, Chiara Bonaguri, Alan J Sinclair, Jesper N Tegnér, Leocadio Rodríguez-Mañas, null null
A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. GeroScience 43 (3) (2021)
John Busby, John G Matthews, Rekha Chaudhuri, Ian D Pavord, Timothy Colin Hardman, Joseph R Arron, Peter Bradding, Christopher E Brightling, David F Choy, Douglas C Cowan, Ratko Djukanovic, Catherine E Hanratty, Tim W Harrison, Cecile T Holweg, Peter H Howarth, Stephen J Fowler, James L Lordan, Adel Hasan Mansur, Andrew Menzies-Gow, Robert M Niven, Douglas S Robinson, Samantha M Walker, Ashley Woodcock, Liam G Heaney, null null
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. The European respiratory journal (2021)
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Luydmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton A Tikhonov, Nadezhda F Khomyakova, Timothy Colin Hardman, Jean-François Rossi
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in context 10 (2021)